Gufic Biosciences Limited – Investor Presentation Summary

Key Operational Highlights

  • Indore manufacturing facility commenced commercial production in October 2024, designed to global regulatory standards
  • US FDA pre-approval inspection completed with three observations being addressed
  • EU GMP audit completed with compliance report submitted, certification awaited
  • 203 product permissions received from State FDA to date, with more in pipeline
  • Tech transfer completed for 40 products, with 27 more products under development
  • 30% capacity utilization target for FY26 on track
  • Manufacturing batch sizes of 100K+ vials/batch vs industry average of 40K

Key drivers of operational performance:

  • Regulated-market readiness with US FDA registration and first product dossier filed
  • Capability extension with depot suite ready for trials and media fills
  • Spray-dried route for lipid-based antifungal near completion
  • Injectable emulsion format through scale-up with exhibit batches planned in Q3

Segment-wise Performance

Hospital Injectable Platform (Critical Care Cluster):

  • AWABAC (first-in-India monobactam and beta-lactamase inhibitor combination) established use within two quarters
  • Anti-infective franchise expanded with rank improvement in echinocandin antifungal class
  • HEAL learning initiative introduced for nursing professionals

Hospital Injectable Platform (Sparsh):

  • In-house manufactured brands now form majority of division's business
  • Dual-chamber bag acceptance widening across national account base
  • Key-account pilot launched in Mumbai for nursing homes segment

Women's Health Platform (Ferticare Cluster):

  • Guficin Alpha retains market leadership in recurrent implantation failure
  • Puregraf group deepened presence in corporate IVF chains
  • Cetrocare introduced in pre-filled syringe presentation

Women's Health Platform (Zenova):

  • Non-injectable, prescription-led brands now carry substantial majority of division
  • Power brands grew ahead of division and contribute larger part of business
  • Fertiforce-M, Fertiforce-F, DD1 SR, Sallaki Max, Gufibis, and Stretchnil gaining traction

Botulinum Toxin Platform (Aesthaderm):

  • Stunnox is second-largest brand in India's aesthetic botulinum toxin segment
  • Indian clinical evidence generated through consensus recommendations and studies
  • Dermal filler range planned for launch in FY27

Botulinum Toxin Platform (Neurocare):

  • Focus on post-stroke spasticity, cerebral palsy, dystonia, chronic migraine and urological indications
  • Registered in Azerbaijan through partner

Nutra, Ayurveda & Others:

  • Sallaki range continued to grow, holding category leadership
  • Gufican Oil was division's fastest-growing brand
  • NaproPure moved into billing and soft launch as first structured entry into allopathic pain management

Financial Highlights

Q2 FY27 Performance:

  • Revenue: ₹288.4 crore
  • EBITDA: ₹49.7 crore
  • PAT: ₹23.5 crore
  • EBITDA Margin: 17.23%
  • PAT Margin: 8.15%

H1 FY27 Performance:

  • Revenue: ₹549.2 crore
  • EBITDA: ₹96.9 crore
  • PAT: ₹46.0 crore
  • EBITDA Margin: 17.64%
  • PAT Margin: 8.38%

YoY Comparison (Q2 FY27 vs Q2 FY26):

  • Revenue growth: 25% (from ₹230.4 crore)
  • EBITDA growth: 31% (from ₹37.9 crore)
  • PAT growth: 58% (from ₹14.9 crore)
  • EBITDA Margin improvement: 78 bps (from 16.45%)
  • PAT Margin improvement: 168 bps (from 6.47%)

Drivers of financial performance:

  • Higher revenue growth across business segments
  • Operational efficiencies from in-house manufacturing
  • Margin quality improvement from own-manufactured brands

Geographical Revenue Split

International Business Achievements Q2 FY27:

  • Saudi Arabia (SFDA): Three registrations (two proton-pump inhibitors and glycopeptide) with first orders received
  • Azerbaijan: Botulinum toxin registered through partner
  • Chile (ISP): Glycopeptide registered through partner with first commercial order
  • UK/Germany: First order secured for echinocandin antifungal
  • Italy: Glycopeptide market entry through partner
  • Portugal, Germany, Spain, Austria, Finland: Macrolide distribution extended through Gufic Ireland
  • Iraq, South Africa: Import-permit orders for hormone and critical-care products

Balance Sheet Snapshot

Not Specified

Capex & Cash Flow Health

  • Indore facility represents significant capital expenditure with annual capacities of 50 million lyophilized injection vials, 30 million liquid injection vials, and 72 million liquid injection ampoules
  • Manufacturing infrastructure includes automated X-ray system and 21-camera inspection line

Strategic & R&D Initiatives

R&D Focus Areas:

  • Peptides & critical API self-reliance (reducing Chinese API dependence)
  • Novel drug delivery systems (NDDS)
  • Clinical programmes

API Development Strategy:

  • Antifungals API: Amphotericin B, Caspofungin, Voriconazole
  • Anticoagulants API: LMWH class development
  • Tetracycline-class antibiotic API
  • Progestins API for Ferticare franchise
  • Beta-3 Adrenergic Agonists, Antidiabetics
  • Cyclopeptide Hormones API

Novel Drug Delivery Systems:

  • Dual Chamber IV Bags: Commercially launched
  • Dual Chamber Syringes: Multiple products in development pipeline
  • Depot Injection (Microspheres): D2/D3 partial agonist LAI, D2 antagonist LAI, GnRH agonist depot, GnRH agonist microsphere, somatostatin analogue in pipeline
  • Liposomal Formulation: Lipid-complex polyene antifungal with US/EU block deal signed

Clinical Programmes:

  • 5 ongoing clinical trials: Reproductive immunology, Botulinum Toxin, Gonadotropin, Wound healing, Phase III biosimilar (rFSH)
  • 12 pipeline clinical studies: NDDS formats, women's health adjacencies, antifungal pipeline, CNS long-acting injectables, antiviral

Industry Trends & Business Environment

  • Shift from distributor-led international model to IP-owned, complex-injectable-led market access model
  • Gufic holds Marketing Authorisation through Gufic Ireland for EU direct access
  • Therapy-basket, multi-country DCP filings instead of single-market filings
  • Three monetization mechanisms: direct supply, out-licensing, and tech-transfer fees

Management Commentary & Growth Outlook

Strategic Outlook:

  • Target to capture 5% market share in identified molecules
  • Medium-term target of 5-10% market share in identified geographies
  • Portfolio expansion building on current high-value molecules
  • Manufacturing scale-up at Indore facility to de-bottleneck Navsari and add new products

Operational Leverage Strategy:

  • Tech transfer to Indore + domestic CMO shift to free Navsari for exports
  • Export volumes ramping as Navsari capacity opens up

Global Partnering:

  • Major global health organization partnership on complex injectable asset for 109 public health markets
  • Strong deal flow across Turkey, Brazil and India for US market via out-licensing and tech transfer